You searched for "intravitreal"
Rebound phenomenon after IVT triamcinolone acetonide for macular oedema
7 April 2021
| Sofia Rokerya
|
EYE - Vitreo-Retinal
In this retrospective study, the authors report the rebound phenomenon after intravitreal triamcinolone acetonide (IVTA) injection for macular oedema secondary to diabetic retinopathy (DR) and central (CRVO) or branch retinal vein occlusion (BRVO). The incidence of a rebound phenomenon was...
3rd Ophthalmic Drug Delivery Summit
28 January 2025
-30 January 2025
Translating Long Lasting Efficacy & Less Invasive Retinal Drug Delivery The importance of matching the right drug delivery route to the right ophthalmic disease is more pressing than ever. The 3rd Ophthalmic Drug Delivery Summit is the premier gathering for...
Stereotactic radiotherapy for polypoidal choroidal vasculopathy
1 August 2015
| Sofia Rokerya
|
EYE - Vitreo-Retinal
Polypoidal choroidal vasculopathy (PCV) is a variant of neovascular AMD. It is a disease of choroidal vasculature characterised by abnormal branching vascular network with aneurysmal dilatations (polyps). Features of PCV include pigment epithelial detachments (PED), subretinal fluid (SRF) accumulation and...
Diabetes macular oedema in pregnancy self-resolving postpartum
1 October 2021
| Rajesh Deshmukh, Antony Raharja, Li Teng Kok
|
EYE - Vitreo-Retinal, EYE - Imaging, EYE - General
*Equally contributing co-first authors. Diabetic macular oedema (DMO) is a common clinical presentation to ophthalmology clinics. Ample evidence exists for management of DMO in non-pregnant patients. However, there is a paucity of evidence on the optimal management of DMO in...
Ozurdex use in noninfectious uveitis
1 June 2016
| Saruban Pasu
|
EYE - Vitreo-Retinal
Burkholder et al. reported the practice patterns of 45 respondents of approximately 176 surveyed members of the American Uveitis Society regarding the use of the Ozurdex implant. Most respondents performed the injection in either a procedure (41.0%) or clinic (23.1%)...
RTP801 as a neuroprotective and axon regenerative treatment
1 April 2016
| Wai Siene Ng
|
EYE - Neuro-ophthalmology
This paper describes the neuroprotective and axon regenerative effects of siRTP801, which is a translatable small-interfering RNA (siRNA) targeting mTOR negative regulator; RTP801, through in-vivo and in-vitro models. In-vivo studies involved an optic nerve crush rat model with intravitreal injections...
ARN in North Africa
1 December 2015
| Saruban Pasu
|
EYE - Vitreo-Retinal
Acute retinal necrosis (ARN) is a rare cause of uveitis. This paper aims to outline the clinical features of 12 patients with ARN in a referral centre in Tunisia, North Africa. A retrospective review of case notes was carried out....
Outcomes of ‘treat and extend’ for neovascular AMD
1 August 2015
| Brian Ang
|
EYE - Vitreo-Retinal
The authors report on 24-month outcomes of anti-vascular endothelial growth factor (anti-VEGF) therapy using a ‘treat and extend’ regime for treatment-naïve neovascular age-related macular degeneration (nAMD). Data for this study was collected from the Fight Retinal Blindness observational registry based...
Effect of anti-VEGF treatment on PED morphology
1 June 2015
| Jaya Myneni
|
EYE - Vitreo-Retinal
This retrospective study of 30 eyes assessed the effect of anti-VEGF on morphology of pigment epithelial detachments (PED) secondary to age-related macular degeneration (AMD). Thirty eyes of 28 patients with PED were compared to 30 eyes of 30 patients with...
Combined anti-VEGF and PDT for wet AMD
1 February 2014
| Brian Ang
|
EYE - Vitreo-Retinal
The authors report on a retrospective case series of combined anti-VEGF and photodynamic therapy (PDT) in the treatment of wet age-related macular degeneration (AMD) refractory to anti-VEGF monotherapy alone. The criteria for treatment failure of anti-VEGF monotherapy were persistent subretinal...
Four year outcomes of macular degeneration treated with ranibizumab
1 February 2014
| Brian Ang
|
EYE - Vitreo-Retinal
The authors report on a retrospective study of neovascular age-related macular degeneration (AMD) patients treated with a variable ranibizumab dosing regimen over a period of four years (from January 2007 to December 2011). A total of 600 treatment naïve eyes...
Subthreshold micropulse laser in BRVO
1 August 2019
| Saruban Pasu
|
EYE - Vitreo-Retinal
The purpose of this retrospective, consecutive, single-centre, non-randomised, and case-control study was to verify the therapeutic effects and safety of oedema (from branch retinal vein occlusion (BRVO)) recurrence suppression effect using 577-nm subthreshold micropulse laser photocoagulation (SMLP) in combination with...